bluebird bio (BLUE)
(Delayed Data from NSDQ)
$0.95 USD
-0.01 (-1.07%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $0.96 +0.01 (0.73%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
BLUE 0.95 -0.01(-1.07%)
Will BLUE be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BLUE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BLUE
bluebird (BLUE) Underperforms Industry YTD Amid Challenges
bluebird (BLUE) Misses on Q4 Revenues, Provides Portfolio Updates
BLUE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline
bluebird (BLUE) Gets $175 Million Loan From Hercules, Shares Up
Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates
Other News for BLUE
TD Cowen says sickle cell therapies may get higher CMS payments
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE), Sarepta Therapeutics (SRPT) and Jazz Pharmaceuticals (JAZZ)
Commit To Buy bluebird bio At $1, Earn 37.8% Annualized Using Options
Is Beam Therapeutics (NASDAQ:BEAM) Too Late to the Game?